Gea introduces industrial-scale equipment for vaccines and blood plasma

GEA has developed numerous innovative improvements to both blood fractionation and vaccine production and brought them to the global market by applying first-class engineering. Fractionating human blood plasma yields purified and concentrated proteins from which drugs or vaccines are then developed. The blood plasma fractionation process is complex and requires in-depth knowledge of both the procedure and the specific equipment needed to achieve high yields in a cost-effective timeframe. In the fight against coronavirus, for example, the administration of antibodies to counter Sars-CoV-2 is a promising treatment option. Once someone has been infected with a virus and recovers, their blood is rich with antibodies. Like a vaccine, giving antibody infused blood plasma to a sick patient could speed up their recovery. The advantage, especially for immunocompromised patients, is that the antibodies have already been produced. The downside, however, is the absolute requirement for a sufficient number of willing donors. However, whether a vaccine induces antibody production or they’re obtained from blood plasma, both approaches ultimately have one thing in common. Once the laboratory work and…

Choose your subscription to read more